Fundraising Fox

Creasallis

4 known investors

Creasallis develops CreaTap, a patented "plug-and-play" antibody modification technology that improves the penetration of antibody-based drugs into solid tumours, applicable to monoclonal, bispecific, and antibody-drug conjugates. It serves biopharmaceutical companies developing oncology therapeutics and is also building its own suite of antibody therapeutics with enhanced tumour penetration.

Biotech

Founders & leadership

ZJZahra Jawad
Zahra JawadinFounder

Investors · 4

BlueYard CapitalBerlin · $500K – $5M
Pace VenturesBerlin · $550K – $1.6Mvia Marius Swart · inferred
ZAKA VCSan Francisco
KdT VenturesreportedAustin · $500K – $3M

In the news

Grey Wolf Therapeutics has raised $49 million Series B. Multus has raised $9.5 million Series A. BlueYard Capital has backed Creassalis.cambridgebiocapital.substack.com · Jan 2023

Frequently asked questions

What does Creasallis do?
Creasallis develops CreaTap, a patented "plug-and-play" antibody modification technology that improves the penetration of antibody-based drugs into solid tumours, applicable to monoclonal, bispecific, and antibody-drug conjugates. It serves biopharmaceutical companies developing oncology therapeutics and is also building its own suite of antibody therapeutics with enhanced tumour penetration.
Who founded Creasallis?
Creasallis was founded by Zahra Jawad.
Who are Creasallis's investors?
Creasallis's investors include BlueYard Capital, Pace Ventures, ZAKA VC, KdT Ventures.